Volume 16, Issue 3, pp. 428-439
- Received July 28, 2016.
- Revision received December 3, 2016.
- Accepted December 27, 2016.
- Published first February 1, 2017.
Copyright & Usage
©2017 American Association for Cancer Research.
View Full Text
- Paul M. Tyler1,
- Mariah M. Servos1,
- Romy C. de Vries1,2,
- Boris Klebanov3,
- Trinayan Kashyap3,
- Sharon Sacham3,
- Yosef Landesman3,
- Michael Dougan4, and
- Stephanie K. Dougan1,*
- 1Dana-Farber Cancer Institute, Boston, Massachusetts.
- 2University of Amsterdam, Program in Biomedical Sciences, Amsterdam, the Netherlands.
- 3Karyopharm Therapeutics, Inc., Newton, Massachusetts.
- 4Massachusetts General Hospital, Boston, Massachusetts.
- ↵*Corresponding Author:
Stephanie K. Dougan, Dana-Farber Cancer Institute, 450 Brookline Ave., Smith 770A, Boston, MA 02215. Phone: 617-582-9609; Fax: 617-582-9610; E-mail:
P.M. Tyler and M.M. Servos contributed equally to this article.